The revenue guidance cut is the dominant signal here, the profit beat is largely cost-driven and not sustainable if top-line momentum continues to decelerate. Watch Q3 trading report on Nov 6 for confirmation of the H2 step-up in Orthopaedics and Bioactives; if US Knee Implants don't inflect, further downside is likely.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $30.44entry
- T+1 · 3mo ago −1.02%α −0.82% · $30.13
- T+5 · 3mo ago −1.41%α −1.31% · $30.01
- T+20 · 3mo ago −4.83%α −3.59% · $28.97
- T+60 · 20d ago −1.12%α −1.49% · $30.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Smith & Nephew reported H1 2026 revenue of $3,097M (+2.3% underlying, +4.6% reported) and Q2 revenue of $1,597M (+1.6% underlying). While trading profit grew 8.1% to $566M and EPSA rose 11.0% to 47.7 cents, the company cut full-year revenue guidance from ~6% to ~4% due to weakness in US Orthopaedics and Advanced Wound Bioactives. The miss on top-line guidance and ongoing structural headwinds in Knee Implants and skin substitutes outweigh the profit beat and $500M buyback, making this a bearish read-through for the stock.
Key Facts
- Q2 underlying revenue growth of 1.6% missed expectations; full-year revenue guidance cut from ~6% to ~4%
- H1 trading profit up 8.1% to $566M, driven by $130M in efficiency savings and tariff refunds
- US Knee Implants declined -7.2% in Q2; US Hip Implants declined -1.5% after four quarters of above-market growth
- Advanced Wound Bioactives revenue fell -12.7% underlying in Q2 due to skin substitute reimbursement changes
- Sports Medicine & ENT remained strong with Q2 underlying growth of 8.6%
- EPSA up 11.0% to 47.7 cents; basic EPS up 6.2% to 35.6 cents
- Free cash flow was $231M, down 5.2% YoY due to $51M increase in capex
- Net debt/EBITDA leverage at 1.8x; $500M buyback announced in May with $216M settled as of Aug 3
- Interim dividend increased 4.0% to 15.6 cents per share
- FDA granted De Novo classification for TESSA Spatial Surgery System
Financial Impact
Full-year revenue guidance cut from ~6% to ~4% growth; trading profit guidance unchanged at ~$1.3B; free cash flow guidance unchanged at ~$800M
Risk Factors
- US Orthopaedics recovery may be slower than guided, especially Knee Implants ahead of LANDMARK launch
- Skin substitute headwind could exceed the upper end of the $20-40M guided range
- Tariff refunds may not repeat in H2, exposing the P&L to the original tariff headwind
- China VBP implementation in H2 2026 could pressure Sports Medicine and ENT growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-089991 |
| Document: 0001104659-26-089991-index-headers.html | 0001104659-26-089991 |
| Document: 0001104659-26-089991-index.html | 0001104659-26-089991 |
| Document: 0001104659-26-089991.txt | 0001104659-26-089991 |
Track record
42 reports on SNN
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers